sábado, 11 de julio de 2009

Breast cancer: percentage of patients for whom tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage II or III hormone receptor positive breast cancer.


TITLE
Breast cancer: percentage of patients for whom tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage II or III hormone receptor positive breast cancer.


SOURCE(S)
ASCO/NCCN quality measures: breast and colorectal cancers. Alexandria (VA): American Society of Clinical Oncology, National Comprehensive Cancer Network, Inc.; 2007 Apr. 5 p.

abrir aquí para acceder al documento completo:
Breast cancer: percentage of patients for whom tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year (365 days) of diagnosis for women with AJCC T1c or stage II or III hormone receptor positive breast cancer.

No hay comentarios: